December 2015, Vol. 4, No. 6
Personalized Medicine in Oncology: Disseminating Essential Information
On behalf of all of us at Personalized Medicine in Oncology (PMO), I’d like to offer our warmest wishes to you this holiday season and our thanks for your loyal readership throughout 2015. Over this past year, we have witnessed advances in our knowledge of tumor biology, biomarkers, and immunotherapies that will ultimately improve our ability to effectively and safely treat patients with cancer.
With these advances, our editorial staff has added departments and enhanced existing ones to improve dissemination of this essential information. These include:
- Interview with the Innovators Series: In each issue, we speak with people making a difference in the field of personalized medicine. From leading researchers and novel diagnostic companies to policy makers and patient organizations, these interviews provide insights to the trends in precision medicine
- Genetic Counseling Column: 2015 saw the launch of our newest department authored by editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center. Ms Radford will address cutting-edge topics in this expanding field
- The Last Word: PMO is a proud partner of the Personalized Medicine Coalition (PMC) and is pleased to host a regular column by the President of the PMC, Edward Abrahams, PhD. Dr Abrahams brings expertise in the policy trends affecting our ability to provide personalized care to our patients
- PersonalizedMedOnc.com: An invaluable resource to our readers, our website includes articles from the journal as well as breaking news stories, conference correspondent highlights, special issues, and videos. I strongly encourage you to subscribe.
It is our continuing hope that our comprehensive services benefit you and ultimately your patients. Thank you for your readership and all the best to you in 2016.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
A closer look at the $2.7 trillion spent on healthcare in the United States in 2011 reveals a system of extreme imbalances, characterized by excessive consumption of care on the one hand and lack of access to necessary care on the other. The Affordable Care Act (ACA), outlined by Otis [ Read More ]
A woman with PIK3CA-mutant triple-negative breast cancer (TNBC), who is an exceptional responder to cetuximab, illustrates how PIK3CA mutations can induce tumor growth by activating the epidermal growth factor receptor (EGFR), and how these cancers may be successfully inhibited by EGFR inhibitors. Joyce O’Shaughnessy, MD, Chair in Breast Cancer Research, [ Read More ]